Form 4: Neurogene Inc. Director Rohan Palekar Acquires Stock Options

Director Rohan Palekar acquired options to purchase 7,700 shares of Neurogene Inc. common stock on June 14, 2024.

Summary

• On June 14, 2024, Rohan Palekar, a director of Neurogene Inc., was granted stock options to purchase 7,700 shares of the company's common stock.
• The exercise price of these options is $42.59 per share.
• The options vest on the earlier of June 14, 2025, or the date of the Issuer's 2025 Annual Meeting of Stockholders, contingent upon Palekar's continued service to the company.
• The options expire on June 14, 2034.
• Following this transaction, Palekar directly owns options for 7,700 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard Form 4 filing indicating a stock option grant, which is a common practice. It doesn't inherently suggest positive or negative implications for the company's performance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Risks

• The value of the stock options is dependent on the future performance of Neurogene Inc.'s stock price.
• If the stock price does not exceed the exercise price of $42.59, the options will have no intrinsic value.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting of the options is tied to the director's continued service, suggesting an expectation of ongoing involvement.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule, contingent on continued service, is also standard practice.
• Comparing the size of the grant (7,700 shares) to similar companies would require further analysis of Neurogene's compensation policies and market capitalization relative to its peers such as BioMarin Pharmaceutical, Sarepta Therapeutics, and Vertex Pharmaceuticals.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
• The impact on other stakeholders is likely minimal.

Key Dates